Best Practice & Research Clinical Haematology
Volume 21, Issue 3 , Pages 503-519 , September 2008

Post-transplant adoptive T-cell immunotherapy

  • Nicole A. Aqui, MD (Director of Apheresis Services, Hospital of the University of PennsylvaniaAssistant Professsor, Department of Pathology and Laboratory Medicine)

      Affiliations

    • Corresponding Author InformationCorresponding author. 272 John Morgan Building, 3620 Hamilton Walk, Philadelphia, PA 19104, USA. Tel.: +1 215 746 1195; Fax: +1 215 746 1100.
    • ,
  • Carl H. June, MD (Director of Translational Research, Abramson Cancer CenterProfessor, Department of Pathology and Laboratory Medicine)

References 

  1. Lum LG. The kinetics of immune reconstitution after human marrow transplantation. Blood. 1987;69:369–380
  2. Storek J, Gooley T, Witherspoon RP, et al. Infectious morbidity in long-term survivors of allogeneic marrow transplantation is associated with low CD4 T cell counts. American Journal of Hematology. 1997;54:131–138
  3. Storek J, Espino G, Dawson MA, et al. Low B-cell and monocyte counts on day 80 are associated with high infection rates between days 100 and 365 after allogeneic marrow transplantation. Blood. 2000;96:3290–3293
  4. Ochs L, Shu XO, Miller J, et al. Late infections after allogeneic bone marrow transplantations: comparison of incidence in related and unrelated donor transplant recipients. Blood. 1995;86:3979–3986
  5. Goldman JM, Gale RP, Horowitz MM, et al. Bone marrow transplantation for chronic myelogenous leukemia in chronic phase. Increased risk for relapse associated with T-cell depletion. Annals of Internal Medicine. 1988;108:806–814
  6. Porrata LF, Gertz MA, Inwards DJ, et al. Early lymphocyte recovery predicts superior survival after autologous hematopoietic stem cell transplantation in multiple myeloma or non-Hodgkin lymphoma. Blood. 2001;98:579–585
  7. Porrata LF, Gertz MA, Litzow MR, et al. Early lymphocyte recovery predicts superior survival after autologous hematopoietic stem cell transplantation for patients with primary systemic amyloidosis. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research. 2005;11:1210–1218
  8. Porrata LF, Ingle JN, Litzow MR, et al. Prolonged survival associated with early lymphocyte recovery after autologous hematopoietic stem cell transplantation for patients with metastatic breast cancer. Bone Marrow Transplantation. 2001;28:865–871
  9. Nordoy T, Husebekk A, Aaberge IS, et al. Humoral immunity to viral and bacterial antigens in lymphoma patients 4–10 years after high-dose therapy with ABMT. Serological responses to revaccinations according to EBMT guidelines. Bone Marrow Transplantation. 2001;28:681–687
  10. Mackall CL, Stein D, Fleisher TA, et al. Prolonged CD4 depletion after sequential autologous peripheral blood progenitor cell infusions in children and young adults. Blood. 2000;96:754–762
  11. Small TN, Papadopoulos EB, Boulad F, et al. Comparison of immune reconstitution after unrelated and related T-cell-depleted bone marrow transplantation: effect of patient age and donor leukocyte infusions. Blood. 1999;93:467–480
  12. Hoyle C, Goldman JM. Life-threatening infections occurring more than 3 months after BMT. 18 UK Bone Marrow Transplant Teams. Bone Marrow Transplantation. 1994;14:247–252
  13. Ketterer N, Espinouse D, Chomarat M, et al. Infections following peripheral blood progenitor cell transplantation for lymphoproliferative malignancies: etiology and potential risk factors. The American Journal of Medicine. 1999;106:191–197
  14. Pavletic ZS, Joshi SS, Pirruccello SJ, et al. Lymphocyte reconstitution after allogeneic blood stem cell transplantation for hematologic malignancies. Bone Marrow Transplantation. 1998;21:33–41
  15. Roux E, Helg C, Dumont-Girard F, et al. Analysis of T-cell repopulation after allogeneic bone marrow transplantation: significant differences between recipients of T-cell depleted and unmanipulated grafts. Blood. 1996;87:3984–3992
  16. Abrahamsen IW, Somme S, Heldal D, et al. Immune reconstitution after allogeneic stem cell transplantation: the impact of stem cell source and graft-versus-host disease. Haematologica. 2005;90:86–93
  17. Hakim FT, Cepeda R, Kaimei S, et al. Constraints on CD4 recovery postchemotherapy in adults: thymic insufficiency and apoptotic decline of expanded peripheral CD4 cells. Blood. 1997;90:3789–3798
  18. Mackall CL, Fleisher TA, Brown MR, et al. Distinctions between CD8+ and CD4+ T-cell regenerative pathways result in prolonged T-cell subset imbalance after intensive chemotherapy. Blood. 1997;89:3700–3707
  19. Mackall CL, Fleisher TA, Brown MR, et al. Age, thymopoiesis, and CD4+ T-lymphocyte regeneration after intensive chemotherapy. The New England Journal of Medicine. 1995;332:143–149
  20. Storek J, Joseph A, Espino G, et al. Immunity of patients surviving 20 to 30 years after allogeneic or syngeneic bone marrow transplantation. Blood. 2001;98:3505–3512
  21. Roux E, Dumont-Girard F, Starobinski M, et al. Recovery of immune reactivity after T-cell-depleted bone marrow transplantation depends on thymic activity. Blood. 2000;96:2299–2303
  22. Janssen EM, Droin NM, Lemmens EE, et al. CD4+ T-cell help controls CD8+ T-cell memory via TRAIL-mediated activation-induced cell death. Nature. 2005;434:88–93
  23. Lichterfeld M, Kaufmann DE, Yu XG, et al. Loss of HIV-1-specific CD8+ T cell proliferation after acute HIV-1 infection and restoration by vaccine-induced HIV-1-specific CD4+ T cells. The Journal of Experimental Medicine. 2004;200:701–712
  24. Mozdzanowska K, Maiese K, Gerhard W. Th cell-deficient mice control influenza virus infection more effectively than Th- and B cell-deficient mice: evidence for a Th-independent contribution by B cells to virus clearance. Journal of Immunology. 2000;164:2635–2643
  25. Kroon FP, van Dissel JT, de Jong JC, et al. Antibody response to influenza, tetanus and pneumococcal vaccines in HIV-seropositive individuals in relation to the number of CD4+ lymphocytes. AIDS (London, England). 1994;8:469–476
  26. Iorio AM, Francisci D, Camilloni B, et al. Antibody responses and HIV-1 viral load in HIV-1-seropositive subjects immunised with either the MF59-adjuvanted influenza vaccine or a conventional non-adjuvanted subunit vaccine during highly active antiretroviral therapy. Vaccine. 2003;21:3629–3637
  27. Avigan D, Pirofski LA, Lazarus HM. Vaccination against infectious disease following hematopoietic stem cell transplantation. Biology of Blood and Marrow Transplantation: Journal of the American Society for Blood and Marrow Transplantation. 2001;7:171–183
  28. Storek J, Dawson MA, Lim LC, et al. Efficacy of donor vaccination before hematopoietic cell transplantation and recipient vaccination both before and early after transplantation. Bone Marrow Transplantation. 2004;33:337–346
  29. Molrine DC, Guinan EC, Antin JH, et al. Donor immunization with Haemophilus influenzae type b (HIB)-conjugate vaccine in allogeneic bone marrow transplantation. Blood. 1996;87:3012–3018
  30. Molrine DC, Guinan EC, Antin JH, et al. Haemophilus influenzae type b (HIB)-conjugate immunization before bone marrow harvest in autologous bone marrow transplantation. Bone Marrow Transplantation. 1996;17:1149–1155
  31. Weiden PL, Flournoy N, Thomas ED, et al. Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts. The New England Journal of Medicine. 1979;300:1068–1073
  32. Dazzi F, Szydlo RM, Cross NC, et al. Durability of responses following donor lymphocyte infusions for patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia. Blood. 2000;96:2712–2716
  33. Collins RH, Goldstein S, Giralt S, et al. Donor leukocyte infusions in acute lymphocytic leukemia. Bone Marrow Transplantation. 2000;26:511–516
  34. Salama M, Nevill T, Marcellus D, et al. Donor leukocyte infusions for multiple myeloma. Bone Marrow Transplantation. 2000;26:1179–1184
  35. Sullivan KM, Storb R, Buckner CD, et al. Graft-versus-host disease as adoptive immunotherapy in patients with advanced hematologic neoplasms. The New England Journal of Medicine. 1989;320:828–834
  36. Kernan NA, Collins NH, Juliano L, et al. Clonable T lymphocytes in T cell-depleted bone marrow transplants correlate with development of graft-v-host disease. Blood. 1986;68:770–773
  37. Giralt S, Estey E, Albitar M, et al. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy. Blood. 1997;89:4531–4536
  38. Dazzi F, Szydlo RM, Craddock C, et al. Comparison of single-dose and escalating-dose regimens of donor lymphocyte infusion for relapse after allografting for chronic myeloid leukemia. Blood. 2000;95:67–71
  39. Porter DL, Levine BL, Bunin N, et al. A phase 1 trial of donor lymphocyte infusions expanded and activated ex vivo via CD3/CD28 costimulation. Blood. 2006;107:1325–1331
  40. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature. 1998;392:245–252
  41. Bretscher P, Cohn M. A theory of self-nonself discrimination. Science (New York, NY). 1970;169:1042–1049
  42. Chen L, Ashe S, Brady WA, et al. Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4. Cell. 1992;71:1093–1102
  43. Riley JL, June CH. The CD28 family: a T-cell rheostat for therapeutic control of T-cell activation. Blood. 2005;105:13–21
  44. Lenschow DJ, Walunas TL, Bluestone JA. CD28/B7 system of T cell costimulation. Annual Review of Immunology. 1996;14:233–258
  45. Kaech SM, Ahmed R. Memory CD8+ T cell differentiation: initial antigen encounter triggers a developmental program in naive cells. Nature Immunology. 2001;2:415–422
  46. Sallusto F, Geginat J, Lanzavecchia A. Central memory and effector memory T cell subsets: function, generation, and maintenance. Annual Review of Immunology. 2004;22:745–763
  47. Fearon DT, Manders P, Wagner SD. Arrested differentiation, the self-renewing memory lymphocyte, and vaccination. Science (New York, NY). 2001;293:248–250
  48. Sallusto F, Lenig D, Forster R, et al. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature. 1999;401:708–712
  49. Klebanoff CA, Gattinoni L, Torabi-Parizi P, et al. Central memory self/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells. Proceedings of the National Academy of Sciences of the United States of America. 2005;102:9571–9576
  50. Monteiro J, Batliwalla F, Ostrer H, et al. Shortened telomeres in clonally expanded CD28-CD8+ T cells imply a replicative history that is distinct from their CD28+ CD8+ counterparts. Journal of Immunology. 1996;156:3587–3590
  51. Van den Hove LE, Van Gool SW, Vandenberghe P, et al. CD57+/CD28- T cells in untreated hemato-oncological patients are expanded and display a Th1-type cytokine secretion profile, ex vivo cytolytic activity and enhanced tendency to apoptosis. Leukemia. 1998;12:1573–1582
  52. Berger C, Jensen MC, Lansdorp PM, et al. Adoptive transfer of effector CD8+ T cells derived from central memory cells establishes persistent T cell memory in primates. The Journal of Clinical Investigation. 2008;118:294–305
  53. Ahmed R, Gray D. Immunological memory and protective immunity: understanding their relation. Science (New York, NY). 1996;272:54–60
  54. Sprent J, Surh CD. T cell memory. Annual Review of Immunology. 2002;20:551–579
  55. Heslop HE, Ng CY, Li C, et al. Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes. Nature Medicine. 1996;2:551–555
  56. Champagne P, Ogg GS, King AS, et al. Skewed maturation of memory HIV-specific CD8 T lymphocytes. Nature. 2001;410:106–111
  57. Appay V, Dunbar PR, Callan M, et al. Memory CD8+ T cells vary in differentiation phenotype in different persistent virus infections. Nature Medicine. 2002;8:379–385
  58. Opferman JT, Ober BT, Ashton-Rickardt PG. Linear differentiation of cytotoxic effectors into memory T lymphocytes. Science (New York, NY). 1999;283:1745–1748
  59. Holmes S, He M, Xu T, et al. Memory T cells have gene expression patterns intermediate between naive and effector. Proceedings of the National Academy of Sciences of the United States of America. 2005;102:5519–5523
  60. Bouneaud C, Garcia Z, Kourilsky P, et al. Lineage relationships, homeostasis, and recall capacities of central- and effector-memory CD8 T cells in vivo. The Journal of Experimental Medicine. 2005;201:579–590
  61. Kono K, Ichihara F, Iizuka H, et al. Expression of signal transducing T-cell receptor zeta molecules after adoptive immunotherapy in patients with gastric and colon cancer. International Journal of Cancer. 1998;78:301–305
  62. Dudley ME, Wunderlich JR, Robbins PF, et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science (New York, NY). 2002;298:850–854
  63. Chang AE, Aruga A, Cameron MJ, et al. Adoptive immunotherapy with vaccine-primed lymph node cells secondarily activated with anti-CD3 and interleukin-2. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 1997;15:796–807
  64. Takayama T, Sekine T, Makuuchi M, et al. Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial. Lancet. 2000;356:802–807
  65. Mazo IB, Honczarenko M, Leung H, et al. Bone marrow is a major reservoir and site of recruitment for central memory CD8+ T cells. Immunity. 2005;22:259–270
  66. Feuerer M, Beckhove P, Bai L, et al. Therapy of human tumors in NOD/SCID mice with patient-derived reactivated memory T cells from bone marrow. Nature Medicine. 2001;7:452–458
  67. Schmitz-Winnenthal FH, Volk C, Z'Graggen K, et al. High frequencies of functional tumor-reactive T cells in bone marrow and blood of pancreatic cancer patients. Cancer Research. 2005;65:10079–10087
  68. Choi C, Witzens M, Bucur M, et al. Enrichment of functional CD8 memory T cells specific for MUC1 in bone marrow of patients with multiple myeloma. Blood. 2005;105:2132–2134
  69. Dhodapkar MV, Krasovsky J, Olson K. T cells from the tumor microenvironment of patients with progressive myeloma can generate strong, tumor-specific cytolytic responses to autologous, tumor-loaded dendritic cells. Proceedings of the National Academy of Sciences of the United States of America. 2002;99:13009–13013
  70. Noonan K, Matsui W, Serafini P, et al. Activated marrow-infiltrating lymphocytes effectively target plasma cells and their clonogenic precursors. Cancer Research. 2005;65:2026–2034
  71. Bevan MJ. Helping the CD8(+) T-cell response. Nature Reviews. 2004;4:595–602
  72. Ossendorp F, Mengede E, Camps M, et al. Specific T helper cell requirement for optimal induction of cytotoxic T lymphocytes against major histocompatibility complex class II negative tumors. The Journal of Experimental Medicine. 1998;187:693–702
  73. Li Y, Bleakley M, Yee C. IL-21 influences the frequency, phenotype, and affinity of the antigen-specific CD8 T cell response. Journal of Immunology. 2005;175:2261–2269
  74. Schoenberger SP, Toes RE, van der Voort EI, et al. T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature. 1998;393:480–483
  75. Hung K, Hayashi R, Lafond-Walker A, et al. The central role of CD4(+) T cells in the antitumor immune response. The Journal of Experimental Medicine. 1998;188:2357–2368
  76. Yee C, Thompson JA, Byrd D, et al. Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells. Proceedings of the National Academy of Sciences of the United States of America. 2002;99:16168–16173
  77. Einsele H, Roosnek E, Rufer N, et al. Infusion of cytomegalovirus (CMV)-specific T cells for the treatment of CMV infection not responding to antiviral chemotherapy. Blood. 2002;99:3916–3922
  78. Rapoport AP, Stadtmauer EA, Aqui N, et al. Restoration of immunity in lymphopenic individuals with cancer by vaccination and adoptive T-cell transfer. Nature Medicine. 2005;11:1230–1237
  79. Miranda-Carus ME, Benito-Miguel M, Llamas MA, et al. Human T cells constitutively express IL-15 that promotes ex vivo T cell homeostatic proliferation through autocrine/juxtacrine loops. Journal of Immunology. 2005;175:3656–3662
  80. Prlic M, Lefrancois L, Jameson SC. Multiple choices: regulation of memory CD8 T cell generation and homeostasis by interleukin (IL)-7 and IL-15. The Journal of Experimental Medicine. 2002;195:F49–F52
  81. Nakajima H, Shores EW, Noguchi M, et al. The common cytokine receptor gamma chain plays an essential role in regulating lymphoid homeostasis. The Journal of Experimental Medicine. 1997;185:189–195
  82. Jiang H, Chess L. An integrated view of suppressor T cell subsets in immunoregulation. The Journal of Clinical Investigation. 2004;114:1198–1208
  83. Shimizu J, Yamazaki S, Sakaguchi S. Induction of tumor immunity by removing CD25+ CD4+ T cells: a common basis between tumor immunity and autoimmunity. Journal of Immunology. 1999;163:5211–5218
  84. Woo EY, Chu CS, Goletz TJ, et al. Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Research. 2001;61:4766–4772
  85. Harrington LE, Hatton RD, Mangan PR, et al. Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nature Immunology. 2005;6:1123–1132
  86. Langowski JL, Zhang X, Wu L, et al. IL-23 promotes tumour incidence and growth. Nature. 2006;442:461–465
  87. McKenzie BS, Kastelein RA, Cua DJ. Understanding the IL-23-IL-17 immune pathway. Trends in Immunology. 2006;27:17–23
  88. Muranski P, Boni A, Antony PA, et al. Tumor-specific Th17-polarized cells eradicate large established melanoma. Blood. 2008;112(2):362–373
  89. Thomas ED. Bone marrow transplantation: a review. Seminars in Haematology. 1999;36(Suppl 7):95–103
  90. Barrett J, Jiang YZ. Allogeneic Immunotherapy for Malignant Diseases. New York: Marcel Dekker, Inc.; 2000;
  91. Fowler DH, Odom J, Steinberg SM, et al. Phase I clinical trial of costimulated, IL-4 polarized donor CD4+ T cells as augmentation of allogeneic hematopoietic cell transplantation. Biology of Blood And Marrow Transplantation: Journal of the American Society for Blood and Marrow Transplantation. 2006;12:1150–1160
  92. June CH, Blazar BR. Clinical application of expanded CD4+ 25+ cells. Seminars in Immunology. 2006;18:78–88
  93. Edinger M, Hoffmann P, Ermann J, et al. CD4+ CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation. Nature Medicine. 2003;9:1144–1150
  94. Zhang L, Conejo-Garcia JR, Katsaros D, et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. The New England Journal of Medicine. 2003;348:203–213
  95. Germeau C, Ma W, Schiavetti F, et al. High frequency of antitumor T cells in the blood of melanoma patients before and after vaccination with tumor antigens. The Journal of Experimental Medicine. 2005;201:241–248
  96. Molldrem JJ, Lee PP, Wang C, et al. Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia. Nature Medicine. 2000;6:1018–1023
  97. Coulie PG, Connerotte T. Human tumor-specific T lymphocytes: does function matter more than number?. Current Opinion in Immunology. 2005;17:320–325
  98. Dummer W, Niethammer AG, Baccala R, et al. T cell homeostatic proliferation elicits effective antitumor autoimmunity. The Journal of Clinical Investigation. 2002;110:185–192
  99. Riddell SR, Greenberg PD. Rapid Expansion Method (“REM”) for In Vitro Propagation of T Lymphocytes US Patent 5,827,642. Washington DC: U.S. Patent Office; 1998;
  100. Schultze JL, Michalak S, Seamon MJ, et al. CD40-activated human B cells: an alternative source of highly efficient antigen presenting cells to generate autologous antigen-specific T cells for adoptive immunotherapy. The Journal of Clinical Investigation. 1997;100:2757–2765
  101. Kim JV, Latouche JB, Riviere I, et al. The ABCs of artificial antigen presentation. Nature Biotechnology. 2004;22:403–410
  102. Levine BL, Bernstein WB, Connors M, et al. Effects of CD28 costimulation on long-term proliferation of CD4 + T cells in the absence of exogenous feeder cells. Journal of Immunology. 1997;159:5921–5930
  103. Weng N, Levine BL, June CH, et al. Regulation of telomerase RNA template expression in human T lymphocyte development and activation. Journal of Immunology. 1997;158:3215–3220
  104. Zhou J, Shen X, Huang J, et al. Telomere length of transferred lymphocytes correlates with in vivo persistence and tumor regression in melanoma patients receiving cell transfer therapy. Journal of Immunology. 2005;175:7046–7052
  105. Kalamasz D, Long SA, Taniguchi R, et al. Optimization of human T-cell expansion ex vivo using magnetic beads conjugated with anti-CD3 and Anti-CD28 antibodies. Journal of Immunotherapy: Official Journal of the Society for Biological Therapy. 2004;27:405–418
  106. Levine BL, Cotte J, Small CC, et al. Large-scale production of CD4+ T cells from HIV-1-infected donors after CD3/CD28 costimulation. Journal of Hematotherapy. 1998;7:437–448
  107. Oelke M, Maus MV, Didiano D, et al. Ex vivo induction and expansion of antigen-specific cytotoxic T cells by HLA-Ig-coated artificial antigen-presenting cells. Nature Medicine. 2003;9:619–624
  108. Luxembourg AT, Borrow P, Teyton L, et al. Biomagnetic isolation of antigen-specific CD8+ T cells usable in immunotherapy. Nature Biotechnology. 1998;16:281–285
  109. Lone YC, Motta I, Mottez E, et al. In vitro induction of specific cytotoxic T lymphocytes using recombinant single-chain MHC class I/peptide complexes. Journal of Hematotherapy. 1998;21:283–294
  110. Dunbar PR, Chen JL, Chao D, et al. Cutting edge: rapid cloning of tumor-specific CTL suitable for adoptive immunotherapy of melanoma. Journal of Immunology. 1999;162:6959–6962
  111. Yee C, Savage PA, Lee PP, et al. Isolation of high avidity melanoma-reactive CTL from heterogeneous populations using peptide-MHC tetramers. Journal of Immunology. 1999;162:2227–2234
  112. Latouche JB, Sadelain M. Induction of human cytotoxic T lymphocytes by artificial antigen-presenting cells. Nature Biotechnology. 2000;18:405–409
  113. Maus MV, Kovacs B, Kwok WW, et al. Extensive replicative capacity of human central memory T cells. Journal of Immunology. 2004;172:6675–6683
  114. Suhoski MM, Golovina TN, Aqui N, et al. Engineering artificial antigen-presenting cells to express a diverse array of costimulatory molecules. Molecular Therapy: The Journal of the American Society of Gene Therapy. 2007;15:981–988
  115. Hirano N, Butler MO, Xia Z, et al. Engagement of CD83 ligand induces prolonged expansion of CD8+ T cells and preferential enrichment for antigen specificity. Blood. 2006;107:1528–1536
  116. Kircher MF, Allport JR, Graves EE, et al. In vivo high resolution three-dimensional imaging of antigen-specific cytotoxic T-lymphocyte trafficking to tumors. Cancer Research. 2003;63:6838–6846
  117. Freitas AA, Rocha B. Peripheral T cell survival. Current Opinion in Immunology. 1999;11:152–156
  118. Williams KM, Hakim FT, Gress RE. T cell immune reconstitution following lymphodepletion. Seminars in Immunology. 2007;19:318–330
  119. Melief CJ. Tumor eradication by adoptive transfer of cytotoxic T lymphocytes. Advances in Cancer Research. 1992;58:143–175
  120. North RJ. Models of adoptive T-cell-mediated regression of established tumors. Contemporary Topics in Immunobiology. 1984;13:243–257
  121. Mackall CL, Gress RE. Pathways of T-cell regeneration in mice and humans: implications for bone marrow transplantation and immunotherapy. Immunological Reviews. 1997;157:61–72
  122. Lee PP, Yee C, Savage PA, et al. Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients. Nature Medicine. 1999;5:677–685
  123. Goldrath AW, Bevan MJ. Low-affinity ligands for the TCR drive proliferation of mature CD8 + T cells in lymphopenic hosts. Immunity. 1999;11:183–190
  124. Surh CD, Sprent J. Homeostatic T cell proliferation: how far can T cells be activated to self-ligands?. The Journal of Experimental Medicine. 2000;192:F9–F14
  125. King C, Ilic A, Koelsch K, et al. Homeostatic expansion of T cells during immune insufficiency generates autoimmunity. Cell. 2004;117:265–277
  126. van Stipdonk MJ, Lemmens EE, Schoenberger SP. Naive CTLs require a single brief period of antigenic stimulation for clonal expansion and differentiation. Nature Immunology. 2001;2:423–429
  127. Ernst B, Lee DS, Chang JM, et al. The peptide ligands mediating positive selection in the thymus control T cell survival and homeostatic proliferation in the periphery. Immunity. 1999;11:173–181
  128. Laport GG, Levine BL, Stadtmauer EA, et al. Adoptive transfer of costimulated T cells induces lymphocytosis in patients with relapsed/refractory non-Hodgkin lymphoma following CD34+-selected hematopoietic cell transplantation. Blood. 2003;102:2004–2013
  129. Schmidt SM, Schag K, Muller MR, et al. Survivin is a shared tumor-associated antigen expressed in a broad variety of malignancies and recognized by specific cytotoxic T cells. Blood. 2003;102:571–576
  130. Vonderheide RH, Hahn WC, Schultze JL, et al. The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes. Immunity. 1999;10:673–679
  131. Mitchison NA. Studies on the immunological response to foreign tumor transplants in the mouse. I. The role of lymph node cells in conferring immunity by adoptive transfer. The Journal of Experimental Medicine. 1955;102:157–177

PII: S1521-6926(08)00057-1

doi: 10.1016/j.beha.2008.07.001

Best Practice & Research Clinical Haematology
Volume 21, Issue 3 , Pages 503-519 , September 2008

Article Tools